

1           **Comprehensive study on the potential environmental risk of temporal**  
2                           **antibiotic usage through wastewater discharges**

3  
4   Elisa Gracia-Marín<sup>1</sup>, Andreu Rico<sup>2,3</sup>, David Fabregat-Safont<sup>1,4</sup>, Francisco J. López<sup>1</sup>, Félix  
5   Hernández<sup>1</sup>, Elena Pitarch<sup>1\*</sup>, Lubertus Bijlsma<sup>1\*</sup>

6  
7   <sup>1</sup> Environmental and Public Health Analytical Chemistry, Research Institute for Pesticides  
8   and Water, University Jaume I, Castelló, Spain

9   <sup>2</sup> IMDEA Water Institute, Science and Technology Campus of the University of Alcalá, Av.  
10   Punto Com 2, Alcalá de Henares 28805, Madrid, Spain

11   <sup>3</sup> Cavanilles Institute of Biodiversity and Evolutionary Biology, University of Valencia, c/  
12   Catedrático José Beltrán 2, 46980, Paterna, Valencia, Spain

13   <sup>4</sup> Applied Metabolomics Research Group, Hospital del Mar Medical Research Institute -  
14   (IMIM), Barcelona, Spain.

15  
16   \*Corresponding authors:

17   Lubertus Bijlsma: [bijlsma@uji.es](mailto:bijlsma@uji.es) ORCID: 0000-0001-7005-8775

18   Elena Pitarch: [epitarch@uji.es](mailto:epitarch@uji.es) ORCID 0000-0002-3343-5815

19  
20  
21   **CONFLICT OF INTEREST**

22   The authors declare they have nothing to disclose.

## 24 **ABSTRACT**

25 Antibiotic residues can reach aquatic ecosystems through urban wastewater discharges,  
26 posing an ecotoxicological risk for aquatic organisms and favoring the development of  
27 bacterial resistance. To assess the emission rate and hazardousness of these compounds, it is  
28 important to carry out periodic chemical monitoring campaigns that provide information  
29 regarding the actual performance of wastewater treatment plants (WWTPs) and the potential  
30 impact of the treated wastewater in the aquatic environment. In this study, 18 of the most  
31 widely consumed antibiotics in Spain were determined by liquid chromatography-tandem  
32 mass spectrometry in both influent (IWW) and effluent wastewater (EWW) samples collected  
33 over four seasons along 2021-2022. Eleven antibiotics were detected in EWW with  
34 azithromycin, ciprofloxacin and levofloxacin showing the highest concentration levels  
35 (around  $2 \mu\text{g L}^{-1}$  of azithromycin and  $0.4 \mu\text{g L}^{-1}$  of quinolone compounds). Data showed that  
36 only 4 out of the 11 compounds were removed by more than 50 % in the WWTP, with  
37 sulfamethoxazole standing out with an average removal efficiency  $> 80 \%$ . The risk that  
38 treated water could pose to the aquatic environment was also assessed, with 6 compounds  
39 indicating a potential environmental risk by exceeding established ecotoxicological and  
40 resistance thresholds. Based on the risk assessment, the WWTP removal efficiency required  
41 to reduce such risk for antibiotics was estimated. In addition, pooled wastewater samples  
42 were screened by LC coupled to high resolution mass spectrometry with ion mobility  
43 separation, searching for metabolites and transformation products of the antibiotics  
44 investigated to widen future research. Studies like this are crucial to map the impact of  
45 antibiotic pollution and to provide the basis for designing water quality and risk prevention  
46 monitoring programs.

47 **Keywords:** Antibiotics; metabolites; sewage; removal efficiency; environmental impact; risk  
48 assessment

## 49 1. INTRODUCTION

50 Undoubtedly, the use of antibiotics has improved human life expectancy during the last  
51 century, as well as decreased mortality from diseases caused by pathogenic bacteria (Aminov,  
52 2010; Elder et al., 2021; Kumar et al., 2019). However, their inappropriate and increasing  
53 usage in human and veterinary medicine have resulted in increasing environmental emissions  
54 and contributed to the antimicrobial resistance burden. The spread of antibiotic resistant  
55 (ABR) bacteria in the human population reduces the success to treat common infectious  
56 diseases and, consequently, can increase mortality and economic costs. The World Health  
57 Organization (WHO) has identified antibiotic resistance as one of the greatest threats to  
58 human health and highlighted the urgency to advance towards a more comprehensive and  
59 accurate assessment and surveillance (WHO, 2023). It is now recognized that the  
60 environment plays a key role in the development and spread of ABR (Elder et al., 2021),  
61 being necessary to improve our knowledge regarding the presence and behaviour of  
62 antimicrobials in environmental compartments (European Commission, 2017).

63 Antibiotics enter the sewage system after consumption and excretion (including their  
64 metabolites) or due to direct disposal. Subsequently, due to incomplete removal by  
65 wastewater treatment plants (WWTPs), antibiotic residues may enter the aquatic environment  
66 through wastewater discharges. Many studies have reported the presence of antibiotics in  
67 different aquatic environments such as surface water (Van Hoi et al., 2021) and reclaimed  
68 water (Campos-Mañas et al., 2017; Martínez-Piernas et al., 2021). Some papers have also  
69 highlighted that antibiotic removal by WWTPs can vary among different locations, even  
70 when using the same treatment processes (Kovalakova et al., 2020; McCorquodale-Bauer et  
71 al., 2023). Hence, advanced treatment processes are required to reduce the negative impact of  
72 antibiotics in aquatic ecosystems (Lien et al., 2016a). However, novel and economic solutions  
73 are currently limited available or not accessible. Therefore, performing regular monitoring

74 campaigns are pivotal to understand the current status and environmental risks posed by these  
75 compounds. In fact, the European Commission included four antibiotics (sulfamethoxazole,  
76 trimethoprim, clindamycin and ofloxacin) in the last Watch List of substances in the field of  
77 water policy (European Commission, 2022), demonstrating the concern about the entry of  
78 these compounds into the environment and their potential consequences for aquatic  
79 ecosystems and human health.

80 Monitoring antibiotics requires the use of highly selective and sensitive analytical techniques,  
81 being liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) one of the  
82 most applied to obtain reliable quantitative data. As indicated above, antibiotics can be  
83 excreted unaltered or as metabolites. It should be noted that metabolites could be found at  
84 higher concentrations than the parent antibiotic, and they may have the same or higher level  
85 of toxicity to the environment than unaltered compound. However, only data on  
86 concentrations of parent compounds are usually reported, but the information on the presence  
87 of metabolites in the aquatic media is crucial to obtain a comprehensive overview of the  
88 current situation (Fabregat-Safont et al., 2023a; Ibáñez et al., 2017, 2021; Löffler et al., 2023;  
89 Wielens Becker et al., 2020). Yet, reference standards of metabolites are not always  
90 available. Under this situation, the complementary quantitative target analysis, usually  
91 focused on parent antibiotics, and the wide-scope screening based on high-resolution mass  
92 spectrometry (HRMS) can provide relevant information on the presence of both antibiotics  
93 and their metabolites (Fabregat-Safont et al., 2023a; Fabregat-Safont et al., 2021).

94 Besides the promotion of antibiotic resistance, antibiotics may pose toxicological effects for  
95 organisms, principally bacteria and primary producers, thus affecting the structure of aquatic  
96 ecosystems and important ecosystem functions such as organic matter decomposition or  
97 nitrification (Le Page et al., 2017; Roose-Amsaleg&Laverman, 2016). Thus, the risk  
98 assessment of antibiotics should combine several protection goals. Few studies have

99 developed ecotoxicological and resistance thresholds for largely used antibiotics based on  
100 laboratory toxicity data for aquatic standard test species and minimum inhibitory  
101 concentrations for pathogenic bacteria, respectively (Bengtsson-Palme & Larsson, 2016; Rico  
102 et al., 2017; Tell et al., 2019). The comparison of ecotoxicological and resistance thresholds  
103 shows that neither is always protective of the other, so both should be preferably used  
104 together to make a holistic risk assessment of antibiotic pollution in areas affected by WWTP  
105 emissions (Le Page et al., 2017). Few studies have demonstrated that concentrations of some  
106 antibiotics measured in aquatic ecosystems impacted by urban or industrial wastewaters can  
107 exceed such thresholds (Fonseca et al., 2020; Hanna et al., 2023; Kelly & Brooks, 2018),  
108 however their use to set effective wastewater treatment methods and processes is to be further  
109 developed.

110 In this work the occurrence of 18 highly consumed antibiotics was investigated in wastewater  
111 samples collected between April 2021 to January 2022 from the WWTP of Castelló (Spain).  
112 The objectives of this study were: 1) to evaluate seasonal variations of concentrations and  
113 removal efficiencies of the antibiotics studied, after conventional wastewater treatment; 2) to  
114 apply a complementary screening of relevant metabolites to better characterize environmental  
115 exposure, using advanced analytical methodology based on HRMS with ion mobility  
116 separation (IMS); 3) to assess risks regarding their potential to contribute to ecotoxicological  
117 effects and antibiotic resistance in the environment, determining the required wastewater  
118 treatment efficiencies that should be achieved to reduce such risks.

## 119 2. MATERIALS AND METHODS

### 120 2.1. Reagents and chemicals

121 The selection of compounds included in this study was based on antibiotic prescription data  
122 in collaboration with the Health Department of Castelló (**Table S1**), and the annual sales data  
123 provided by suppliers and the Pharmacy Services of Castelló (Spain) (**Table S2**). Such  
124 information is summarized in **Figure 1**, where it is observed that  $\beta$ -lactams and macrolides  
125 were the main families of antibiotics prescribed during 2020.

126 Finally, 18 antibiotics were chosen to be part of this study: amoxicillin, ampicillin,  
127 azithromycin, cefditoren (purchased as cefditoren pivoxil), cefuroxime, ciprofloxacin,  
128 clarithromycin, clindamycin, cloxacillin, doxycycline, erythromycin, levofloxacin,  
129 metronidazole, moxifloxacin, norfloxacin, roxithromycin, sulfamethoxazole and  
130 trimethoprim. Isotopically-labelled analogues (**Table S3**) were used as internal standards  
131 (ILIS) for each selected antibiotic, with the exception of cefditoren. All the analytical  
132 reference standards were purchased from LGC (Teddington, UK) and Merck (Darmstadt,  
133 Germany). Methanol, acetonitrile and formic acid (LC-MS grade) and ammonium acetate (>  
134 98 %) were acquired from Scharlab (Scharlab, Barcelona, Spain). LC-MS grade water was  
135 obtained using an Ultramatic Plus GR from Wasserlab (Navarra, Spain).

### 136 2.2. Description of the WWTP

137 The selected WWTP (39°59'09.2"N 0°0'21.8"W) treats urban wastewater from Castelló de la  
138 Plana and Borriol (Spain) and serves a population of 179,661 inhabitants (based on census  
139 data of 2020 (Instituto Nacional de Estadística, 2023)). The WWTP applies a conventional  
140 treatment consisting of a basic biological process and has a treatment capacity of 45,000 m<sup>3</sup> /  
141 day. The water line includes a pretreatment (roughing filtration, desanding and degreasing), a  
142 primary treatment (primary sedimentation), a conventional activated sludge biological

143 treatment, followed by a tertiary treatment (operated with sand filtration and ultraviolet  
144 oxidation). Finally, the treated water is discharged into the Mediterranean Sea or used to  
145 irrigate parks and gardens after tertiary treatment with an additional chlorination step.

### 146 **2.3. Wastewater samples**

147 24-h composite samples of influent wastewater (IWW) and effluent wastewater (EWW) were  
148 collected from the WWTP, from April to October 2021 and during January 2022, covering  
149 the four seasons. Wastewater sampling was carried out two weeks per month (only in one  
150 week in August) collecting IWW and EWW samples of two days each week. A total of 30  
151 IWW and 30 EWW samples were analysed. **Table S4** shows the sampling dates, and the flow  
152 rates of the WWTP on these days.

153 All samples were collected in high-density polyethylene bottles, stored at -20 °C, and  
154 transported to the laboratory when the last sample of the week was collected. After reception  
155 in the laboratory, samples were stored in the dark at -20 °C until analysis.

### 156 **2.4. Instrumentation**

#### 157 *2.4.1. LC-MS/MS*

158 An Acquity UPLC<sup>TM</sup> H-Class liquid chromatography system (Waters Corp., Milford, MA,  
159 USA) interfaced to a triple quadrupole mass spectrometer Xevo TQ-S<sup>TM</sup> (Waters Corp.,  
160 Manchester, UK) and equipped with an orthogonal Z-Spray electrospray ionization interface  
161 (ESI) (Waters Corp, Manchester, UK) was used for quantitative sample analysis. MS/MS  
162 conditions are shown in **Table S3**. Further information regarding antibiotic determination,  
163 analytical method and validation can be found in the literature (Fabregat-Safont et al.,  
164 2023b).

165

166

#### 167 2.4.2. LC-IMS-HRMS

168 Metabolite screening was performed using an Acquity UPLC™ I-Class system (Waters  
169 Corp., Milford, MA, USA) coupled to a Vion IMS QTOF mass spectrometer (Waters Corp.,  
170 Wilmslow, Manchester, UK), using an ESI interface operating in both positive and negative  
171 ionization modes. Further information regarding instrumentation, data treatment, results  
172 evaluation and compound identification is described in the literature (Celma et al., 2020;  
173 Fabregat-Safont et al., 2021; Lopez et al., 2022).

#### 174 2.5. Sample analysis

175 For quantification, samples were analysed by direct injection (DI)-LC-MS/MS based on a  
176 previously developed methodology (Fabregat-Safont et al., 2023b). Briefly, a volume of 2  
177 mL of centrifuged wastewater was 5-fold (IWW) or 2-fold (EWW) diluted with ultrapure  
178 water, taking 200 µL IWW or 500 µL EWW, adding 40 µL of ILIS mixture 5 µg L<sup>-1</sup> and  
179 adjusting the volume to 1 mL with ultrapure water. Finally, 100 µL of the diluted samples  
180 were injected into the LC-MS/MS system.

181 For metabolite screening analyses by LC-IMS-HRMS, two IWW and two EWW pooled  
182 samples were prepared by mixing individual samples as follows: the first IWW pooled  
183 sample was prepared using two randomly selected samples, collected one in April and the  
184 other one in May 2021; and the second IWW pooled sample using samples collected in June  
185 and July 2021. The same strategy was used for EWW, mixing the corresponding EWW  
186 samples. Sample treatment was performed using 100 mL of sample (2-fold diluted with  
187 ultrapure water to avoid clogging) and passed by gravity through an Oasis HLB 200 mg  
188 cartridge (Waters Corp.). Cartridges were eluted with 10 mL of methanol, evaporated to



189 dryness at 40 °C under gentle nitrogen stream, and redissolved in 500 µL of water:methanol  
190 (90:10, v:v). Finally, 10 µL of sample extract was injected in the LC-IMS-HRMS system.

191 For compound identification in the screening, an in-house database containing information  
192 about the major metabolites reported for these antibiotics was used, following the analytical  
193 strategy described in literature (Fabregat-Safont et al., 2023a; Fabregat-Safont et al., 2021;  
194 Lopez et al., 2022). More details about the confidence levels of the metabolite identification  
195 can be found in identification Celma et al. (2020) and in section 2.5 of the Supporting  
196 Information.

## 197 **2.6. Estimation of removal efficiencies**

198 The removal efficiency (RE) of the WWTP was estimated by comparing the daily mass loads  
199 of antibiotics in IWW and EWW, estimated from the daily antibiotic concentrations and the  
200 WWTP flow rates (m<sup>3</sup>/24 h). RE was calculated using **Eq. 1**, where  $q_I$  is the daily mass load  
201 (g/24h) of IWW at day  $x$  and  $q_E$  is the mass load of EWW at day  $x + 1$ , assuming a residence  
202 time at the WWTP of approximately 24h.

$$203 \quad RE (\%) = \frac{q_I - q_E}{q_I} \times 100 \text{Eq. 1}$$

204 A concentration equivalent to half the quantification value (or the daily load corresponding to  
205 this concentration value) was considered for the calculation of RE of an antibiotic detected  
206 i.e., above its limit of detection (LOD) but below its limit of quantification (LOQ).

## 207 **2.7. Risk assessment**

208 Antibiotic concentrations in WWTP effluents were compared with Predicted No Effect  
209 Concentrations for ecotoxicological effects ( $PNEC_{ecotox}$ ) and the promotion of antibiotic  
210 resistance ( $PNEC_{resistance}$ ).  $PNEC_{ecotox}$  values were obtained from (Tell et al., 2019), which  
211 had been derived from laboratory toxicity data for cyanobacteria (NOEC; growth inhibition)

212 divided by an assessment factor of 10 following the recommendations established by the  
213 European Chemicals Agency (ECHA) (2008) and the European Commission (2018). For  
214 some compounds, the  $PNEC_{ecotox}$  was not available (e.g. levofloxacin, moxifloxacin). For  
215 these, the  $PNEC_{ecotox}$  was derived from published toxicity data for *Microcystis sp.* following  
216 the same approach (**Table 1**).

217  $PNEC_{resistance}$  values were obtained from Bengtsson-Palme & Larsson (2016, which were  
218 derived from Minimum Inhibitory Concentrations (MICs) obtained from the European  
219 Committee on Antimicrobial Susceptibility Testing (EUCAST) database (EUCAST, 2022).  
220 The method applied (Bengtsson-Palme & Larsson, 2016) uses the 1% lowest observed MICs  
221 rounded down to the lowest concentration in the EUCAST testing scale after application of  
222 an assessment factor of 10. Besides the  $PNEC_{resistance}$  proposed by Bengtsson-Palme &  
223 Larsson (2016), we also implemented the method proposed by Rico et al. (2017) to derive  
224  $PNEC_{resistance}$  values, which is based on the calculation of the Hazardous Concentration for  
225 the 5% (HC5) of the estimated minimum selective concentrations for bacteria. Similarly to  
226 Bengtsson-Palme & Larsson (2016), the minimum selective concentrations (MSC) for each  
227 bacterial taxon is extrapolated from the MIC data available in the EUCAST database  
228 applying an assessment factor of 10. However, a log-normal distribution is then fitted to the  
229 MSCs extrapolated for the bacteria included in the EUCAST database. To implement this  
230 method, the MIC data for the antibiotics found in the WWTP effluents was downloaded from  
231 the EUCAST database (EUCAST, 2022; **Table S5**). The taxa for which there were less than  
232 30 MIC observations for each antibiotic were removed. Then the lowest MIC for each taxon-  
233 antibiotic combination was derived. The lowest MIC was defined as the lowest MIC from the  
234 available MICs reported in the different studies that contained at least 10 observations. Such  
235 approach was implemented to reduce the risk of including individual, low MIC values that  
236 may be considered outliers or flawed too much the MIC distribution. Next, the MSC was

237 derived by dividing the lowest MIC for each taxon-antibiotic combination by an extrapolation  
238 factor of 10. Finally, a log-normal distribution was fitted to the MSC data available for  
239 antibiotic to calculate the HC5 and their lower (5%) and upper (95%) confidence limits using  
240 the ETX2.3 software (Van Vlaardingen et al., 2004) and the methods described by Aldenberg  
241 & Jaworska 2000). The lower confidence limit of the calculated HC5 interval was chosen as  
242 the  $PNEC_{resistance}$ , assuming that this is the maximum concentration that prevents the  
243 development of antibiotic resistance in environmental bacteria.

244 The empirical cumulative distribution functions for the measured antibiotic concentrations in  
245 the WWTP effluents were compared with the ecotoxicological and resistance PNECs. We  
246 calculated the percentage of samples that exceeded both threshold concentrations.  
247 Furthermore, we estimated the antibiotic removal efficiencies that should be implemented at  
248 the studied WWTP to produce effluent concentrations below the lowest antibiotic threshold,  
249 considering both ecotoxicological and antimicrobial resistance effects.

## 250 3. RESULTS AND DISCUSSION

### 251 3.1. Determination of antibiotics in IWW and EWW

#### 252 *Analytical quality assurance*

253 In this work, special attention was paid to the quality of the analysis to support the reliability  
254 of the results (Hernández et al., 2023). To this aim, quality control (QC) samples were  
255 prepared from four real “blank” wastewater samples of different type (IWW and EWW), each  
256 spiked at three different concentration levels, 100, 500 and 5000 ng L<sup>-1</sup>. All samples,  
257 including the “blank” samples for preparing the QCs, were analysed in 4 different sequences.

258 QCs recoveries in both IWW and EWW were mainly between 60 and 140%, which is the  
259 acceptability range for individual recoveries of control samples according to the SANTE  
260 guideline (SANTE, 2021)(**Table S6**). In some cases, the calculation of QCs recovery at the  
261 low concentration (100 ng L<sup>-1</sup>) was problematic due to the presence of the analyte in the  
262 “blank” sample used for the QC preparation at concentration similar or higher than the spiked  
263 level (*e.g.*, azithromycin, clarithromycin, erythromycin, roxithromycin and cefditoren)  
264 (Hernández et al., 2023). As an example, the antibiotics clarithromycin and azithromycin  
265 showed recoveries slightly below 60% (between 51 to 56%) in QCs prepared at the low and  
266 medium concentrations. These two compounds were present at high concentrations in the  
267 samples, except for some EWW where clarithromycin was found at lower concentration  
268 levels, but still above 100 ng L<sup>-1</sup>, and therefore no correction factor was applied for its  
269 quantification. Furthermore, Cefuroxime showed anomalous QCs at 100 ng L<sup>-1</sup> in EWW QC  
270 samples, therefore no average value has been reported. Relative standard deviations (RSDs)  
271 (see **Table S6**) were mostly below 20-25%, although greater variations could be observed for  
272 some antibiotics, especially in IWW samples (*e.g.*, clindamycin and metronidazole). It is  
273 worth noting that data presented in Table S6 do not correspond to replicates of the same

274 sample (*i.e.*, repeatability), but to individual data from different samples analysed throughout  
275 this study.

### 276 *Occurrence of antibiotics in IWW and EWW samples*

277 The 18 antibiotics were analyzed in IWW and EWW samples collected in the different  
278 campaigns. From their concentrations, the daily mass loads were calculated by multiplying  
279 them by the daily flow rate ( $\text{m}^3/\text{day}$ ) entering the WWTP. This is typically applied to correct  
280 for dilution factors related to the sewage system and weather conditions (*i.e.*, rainwater).  
281 Concentrations and mass loads of antibiotics can be found in **Tables S7** to **S10**. As it is  
282 described in section 2.5, the samples were centrifuged before analysis, so the results shown  
283 correspond to the dissolved phase of wastewater samples. Although analysis of both liquid  
284 and solid phases surely provides a more accurate estimation of removal efficiency, the  
285 medium-high polarity of the antibiotics selected imply that they are more soluble in the  
286 aqueous phase, and hardly absorbed to the suspended particles. This suggests that analysis of  
287 the particulate phase should not significantly modify the results presented in this work.

288 Antibiotics belonging to the  $\beta$ -lactam family were not detected in any of the samples  
289 analyzed, including amoxicillin, one of the most consumed antibiotics in Spain. This fact  
290 could be related to the poor stability of these compounds in aqueous samples (Fabregat-  
291 Safont et al., 2023b), which might be explained by the limited stability of the  $\beta$ -lactam ring,  
292 common to all antibiotics belonging to this family of antibiotics (Lien et al., 2016b; Zuccato  
293 et al., 2005). Furthermore, the tetracycline doxycycline and the macrolide roxithromycin  
294 were not found in any sample, and the quinolone moxifloxacin was only found in EWW.

295 In IWW samples, five antibiotics (azithromycin, ciprofloxacin, clarithromycin,  
296 levofloxacin/ofloxacin and sulfamethoxazole) were detected in all the samples analyzed and  
297 exceeded the concentration level of  $1 \mu\text{g L}^{-1}$  in at least one sample. The compounds with

298 highest concentrations in IWW, also showed the highest levels in the corresponding EWW  
299 samples, generally below  $1 \mu\text{g L}^{-1}$  (except for azithromycin, up to  $4 \mu\text{g L}^{-1}$ ), which revealed  
300 low elimination rates in the WWTP. Our results are in accordance with a study from Italy  
301 (Zuccato et al., 2010) where clarithromycin, sulfamethoxazole, and the fluoroquinolones  
302 ciprofloxacin and levofloxacin/ofloxacin were the most abundant antibiotics in the four  
303 WWTPs investigated. Similarly, in another European research (Rodriguez-Mozaz et al.,  
304 2020), fluoroquinolones were observed at the highest concentrations in Portugal and Cyprus,  
305 while the macrolides azithromycin and clarithromycin were found in all the seven studied  
306 countries, Spain among them.

307 As can be observed in **Tables S9** and **S10**, the sum of the daily mass loads (g/day) of the  
308 detected antibiotics varies depending on the sampling day. In the case of the IWW samples,  
309 the values ranged from 89 to 453 g/day, highlighting the samples of May (I-007, I-010 and I-  
310 011) and June (I-013 and I-014) with the highest sum of daily loads, in all cases higher than  
311 400 g/day. As regards to the EWW samples, the values were lower, between 46 to 250 g/day,  
312 with the highest total daily loads ( $\geq 200$  g/day) in May (E-011 and E-012) and June (E-014  
313 and E-015) as well. **Figure 2** shows the annual evolution of the daily mass load (as sum of  
314 antibiotics and antibiotic families) in both IWW and EWW samples ( $\beta$ -lactams are not  
315 included in this figure because they were not found in any of the samples). Macrolides were  
316 the antibiotics found at the highest mass loads, followed by the fluoroquinolones. The  
317 evolution profile of both families was similar to the sum of antibiotics in both water types,  
318 observing a decrease in mass loads at the end of summer (i.e., September) and reaching  
319 higher levels again in January. This data is consistent with Spanish data on antibiotic  
320 resistances (Plan Nacional Resistencia Antibioticos (PRAN), 2023) and described by (Solaun  
321 et al., 2022), where a decline in antibiotic prescription is observed annually with the approach  
322 of summer and a considerable increase is observed in January. The rest of antibiotics showed

323 a more regular pattern, although the highest daily mass loads were also reached in January,  
324 especially in IWW samples.

325 The antibiotics concentrations found in wastewater samples are in the line of other recent  
326 studies performed around the world (**Table S11**) and illustrate the anthropogenic impact of the  
327 use of pharmaceuticals on urban wastewaters. Considering this widely reported issue, only the  
328 efficient removal efficiency in the WWTPs would allow to minimize the potential negative  
329 impact on the aquatic environment.

### 330 *Removal efficiencies*

331 RE of the WWTP for the selected antibiotics was estimated as described in section 2.6 (see  
332 **Tables S9** and **S10** for daily mass loads). The obtained results for the WWTP RE of the  
333 selected antibiotics are shown in **Figure 3**. In order to facilitate the visualization, RE was  
334 considered equal to 0% when a compound was undetected in IWW, but it could be quantified  
335 in EWW (e.g. a common situation for clindamycin, metronidazole and moxifloxacin). The  
336 RE estimated in the different campaigns were rather variable, particularly for some  
337 compounds (e.g. trimethoprim), which could be due to some factors that affect the WWTP  
338 removal, such as temperature and hydraulic retention time (Subedi et al., 2014; Vieno et al.,  
339 2007). Highly variable elimination was also observed in another WWTP for some  
340 compounds with no clear tendency along three sampling campaigns (Bijlsma et al., 2021).  
341 The highest variability in the RE estimated in the different monitoring campaigns occurred  
342 for trimethoprim and specially for metronidazole as shown in **Figure 3**.

343 The average RE was above 50% for five antibiotics (azithromycin, clarithromycin,  
344 ciprofloxacin, norfloxacin, sulfamethoxazole), with sulfamethoxazole being efficiently  
345 eliminated (RE around 80%). On the contrary, erythromycin, levofloxacin/ofloxacin and  
346 trimethoprim were poorly removed with mean RE below 30%. These data and the variability

347 observed in RE are in line with other data reported in the literature (Behera et al., 2011;  
348 Pereira et al., 2020; Bijlsma et al., 2021; Karthikeyan & Meyer, 2006; Seifrtová et al., 2010;  
349 Zuccato et al., 2010; Lopez et al., 2022). In the case of moxifloxacin, its non-elimination  
350 observed in the present study does not agree with studies performed in US and China (He et  
351 al., 2015; Yan et al., 2014), where an elimination around 50% was reported.

352 Three compounds (moxifloxacin, clindamycin, and metronidazole) showed no elimination  
353 (**Figure 3**). RE=0 or even negative RE may be explained by the fact that removal in a WWTP  
354 is not only related to the treatment applied but also to the physic-chemical properties of the  
355 compounds (such as pKa, log  $K_{ow}$  and biodegradability) (Desbiolles et al., 2018; Rodriguez-  
356 Mozaz et al., 2020). It is challenging to link the antibiotics' physicochemical characteristics  
357 to the RE attained in an activated sludge system since many variables are involved (Verlicchi  
358 et al., 2012). Although more polar compounds (log  $K_{ow}$  < 2.5) usually have low sorption  
359 potential (Rogers, 1996), fluoroquinolones (log  $K_{ow}$  < 1; see **Table S3**) could bind to the  
360 sludge due to their zwitterionic character (Golet et al., 2003), causing low or even negative  
361 elimination from the WWTP (Golovko et al., 2021; Sabri et al., 2020a; Zuccato et al., 2010),  
362 as it has been observed for moxifloxacin in the present study. Negative efficiencies obviously  
363 imply that no removal occurs in the WWTP. The fact that EWW present higher  
364 pharmaceutical concentrations than IWW may be due to the cleavage of phase II metabolites,  
365 such as glucuronides and sulphates (Lacey et al., 2008; Vieno et al., 2007), during wastewater  
366 treatment, releasing thus parent compound and increasing their concentrations after treatment  
367 (Yan et al., 2014). The low removal found for metronidazole may be justified by its high  
368 solubility in water (log  $K_{ow}$  -0.02) and its low biodegradability. This compound is considered  
369 a difficult pollutant to be eliminated by using only conventional treatments (Lien et al.,  
370 2016a).

371



## 372 3.2. Metabolite screening

373 In this work, four antibiotic metabolites were tentatively identified in the screening based on  
374 the exact mass information provided by HRMS, interpretation of the fragmentation observed  
375 and agreement with ion fragments reported in the literature.

### 376 *3-desmethyl trimethoprim*

377 Trimethoprim undergoes oxidative metabolism, with the demethylated 3'- and 4'- metabolites  
378 accounting for approximately 65% and 25% of the total metabolite formation, respectively  
379 (Goldman et al., 2015). After oral administration, 50% to 60% of trimethoprim is excreted in  
380 urine within 24 hours, approximately 80% of which is unchanged parent drug (FDA, 2016).  
381 The identification of this metabolite was based on the presence of two common fragment ions  
382 shared with trimethoprim, at  $m/z$  261 and 123, establishing thus the position of the  
383 demethylation (**Table 2, Figure 4A**). Nevertheless, it cannot be assured which is the  
384 demethylated methoxy group, as the three moieties can be metabolized and will produce the  
385 same fragmentation (compound identified at Level 3).

### 386 *Clindamycin sulfoxide*

387 Clindamycin is mainly metabolized in the liver CYP3A4 and CYP3A5 (FDA, 2019),  
388 producing two inactive metabolites: clindamycin sulfoxide and *N*-desmethyl clindamycin  
389 (FDA, 2019). Approximately 10% of unchanged clindamycin is excreted in the urine, 3.6%  
390 in the feces, and the remaining as inactive metabolites (FDA, 2019). The identification of this  
391 metabolite was based on the presence of two common fragment ions shared with clindamycin  
392 at  $m/z$  126 and 377. The diagnostic ion  $m/z$  377 establishes the position of the oxide group, a  
393 sulfoxide in this case (**Table 2, Figure 4B**). Additionally, the observed isotope pattern fits  
394 with the presence of Cl and S atoms in the compound structure, similarly to clindamycin  
395 (compound identified at Level 2b).

396 *N-acetyl ciprofloxacin and oxociprofloxacin*

397 Ciprofloxacin is primarily metabolized by CYP1A2 (FDA, 2021), producing  
398 oxociprofloxacin and sulociprofloxacin (3-8% of the total dose each) (FDA, 2021).  
399 Ciprofloxacin is also metabolized to desethylene ciprofloxacin and formylciprofloxacin (both  
400 minor) (FDA, 2021), being together with the previously mentioned metabolites the 15% of a  
401 total oral dose (FDA, 2021). Unchanged ciprofloxacin resulted in 45% recovery in urine and  
402 62% recovery in feces (LeBel, 1988). In this work, the metabolite *N*-acetyl ciprofloxacin was  
403 identified based on one shared fragment ion with the parent ciprofloxacin at  $m/z$  231,  
404 establishing thus the position of the biotransformation (compound identified at Level 2b)  
405 (**Table 2, Figure S1A**). For oxociprofloxacin, no common shared fragment ions were  
406 observed. Nevertheless, the three observed ion fragments were justified based on its proposed  
407 structure, although the oxo group could be located in different parts of the piperazine ring  
408 (compound identified at Level 3) (**Table 2, Figure S1B**).

409 **3.3. Antibiotic risk assessment**

410 The comparison of measured antibiotic concentrations with environmental thresholds shows  
411 that 6 out of the 11 antibiotics detected in the WWTP effluents exceeded either the  
412 ecotoxicological or the resistance thresholds. The antibiotics with the highest percentage of  
413 exceedances were azithromycin and clarithromycin (exceedance in 100% of samples),  
414 followed by ciprofloxacin (97%), norfloxacin (77%), metronidazole (70%) and  
415 levofloxacin/ofloxacin (63%; **Table 1**). Azithromycin and clarithromycin exceeded both the  
416  $PNEC_{ecotox}$  and the  $PNEC_{resistance}$  in all cases, while ciprofloxacin exceeded the  $PNEC_{resistance}$   
417 in 97% of cases and the  $PNEC_{ecotox}$  in 7% of them (**Figure 5**). The calculated risks for the rest  
418 of compounds were driven by the exceedance of the resistance thresholds. The magnitude of  
419 exceedances ranged from about 3 for metronidazole and levofloxacin, to 209 for  
420 azithromycin.

421 Except for metronidazole, which is often used to treat bacterial vaginosis, the compounds  
422 showing the highest potential risk belong to the macrolide and quinolone groups, which are  
423 classified as antibiotics of critical importance for human health (WHO, 2019). Other studies  
424 have also pointed to these compounds as major contributors to resistance development in  
425 aquatic ecosystems. For example, Fonseca et al. (2020) identified azithromycin, ciprofloxacin  
426 and norfloxacin as the most hazardous compounds in surface waters of the Mijares River  
427 (Spain) based on a similar approach. Other studies assessing the environmental risks of  
428 ciprofloxacin at a global scale based on a literature review showed that 58% of municipal  
429 effluents exceeded the established resistance threshold, while 16% the ecotoxicity one (Kelly  
430 and Brooks 2018). A more recent study on the environmental occurrence of antibiotics and  
431 other pharmaceuticals in surface waters of 104 countries showed that 70% of the monitored  
432 antibiotics exceeded resistance thresholds in at least one location, and pointed at  
433 ciprofloxacin, clarithromycin, enrofloxacin (a quinolone mostly used in veterinary medicine)  
434 and metronidazole as the compounds showing the largest potential contribution to antibiotic  
435 resistance in European surface waters (Wilkinson et al., 2022).

436 Differences between the resistance thresholds calculated by Bengtsson-Palme & Larsson  
437 (2016) and those derived based on the HC5 of the MSC distribution according to Rico et al.  
438 (2017) varied for the different compounds and were, in most cases, within a factor of 2,  
439 suggesting that both approaches yield similar results and that none of the two is consistently  
440 lower or higher than the other. To date, the number of experimentally-derived MSCs that can  
441 be used to validate the theoretical approaches used by these two methods to establish  
442 environmental thresholds is very limited (but see (Gullberg et al., 2011; Liu et al., 2011)).  
443 Therefore, further experimental approaches are needed to generate MSC and to calculate  
444 MIC-MSC extrapolation ratios to refine risk calculations for the antibiotics that show a

445 higher contribution to the environmental resistance burden, such as ciprofloxacin,  
446 azithromycin, or clarithromycin.

447 To protect environmental and public health it is important to assess the degree of selection  
448 pressure by antibiotic pollution in different scenarios (Pruden et al., 2013). The outcomes of  
449 this study suggest that the emission point of these WWTP effluents constitute a marine  
450 hotspot for ecotoxicological impacts and antibiotic resistance development, where cumulative  
451 impacts may be expected due to co-exposures and the continuous nature of the WWTP  
452 effluent emission. The extension and magnitude of such impact at the discharge point will  
453 also depend on factors such as water depth, currents, or sediment characteristics. By applying  
454 a precautionary approach that considers minimal dilution in the aquatic environment, our  
455 study shows that efforts are needed to eliminate antibiotic residues during the wastewater  
456 treatment process. Based on the lowest PNEC as benchmark, we estimated target REs of  
457 approximately 60% for levofloxacin/ofloxacin and metronidazole, 80% for clarithromycin,  
458 and above 90% for azithromycin and ciprofloxacin. These elimination targets should be  
459 added to the elimination percentages already achieved by the conventional wastewater  
460 treatment methods implemented at the WWTP. In this work, most antibiotics were partially  
461 removed in the WWTP, therefore additional treatments would be required to reach the targets  
462 RE estimated in this study. Thus, conventional treatments may need optimization or advanced  
463 treatments should be implemented to improve RE (Sabri et al., 2020b), such as microfiltration  
464 and reverse osmosis (Golovko et al., 2021; Watkinson et al., 2007), phytoremediation  
465 (McCorquodale-Bauer et al., 2023) or advanced oxidation processes, ultraviolet radiation, or  
466 ozonation (Gao et al., 2012; Luo et al., 2014).

467

468

469

470

#### 471 **4. CONCLUSIONS**

472 A comprehensive monitoring study has been carried to assess the input and environmental  
473 emission of antibiotics in a conventional WWTP. Azithromycin, ciprofloxacin,  
474 clarithromycin, levofloxacin/ofloxacin and sulfamethoxazole were the antibiotics found at the  
475 highest concentrations. The measured antibiotic concentrations were relatively constant  
476 throughout the year, with a decline at the end of the summer season, which highlights the  
477 potential of these kind of analyses to reflect antibiotic consumption patterns. The estimation  
478 of the WWTP removal efficiency revealed that only 5 antibiotics (sulfamethoxazole,  
479 norfloxacin, clarithromycin, ciprofloxacin and azithromycin) were eliminated above 50%,  
480 being sulfamethoxazole the only compound that could be considered completely eliminated  
481 (RE approximately 80%). About half of the detected compounds exceeded ecotoxicological  
482 and/or resistance thresholds, being azithromycin, clarithromycin, and ciprofloxacin the  
483 compounds that showed the largest number of exceedances. In total, 18 compounds were  
484 monitored, 11 detected and 6 exceeded PNEC. Despite the RE for these compounds was  
485 notable (> 40%), this study recommends the application of advanced treatment technologies  
486 to meet the proposed ecotoxicological and resistance standards. An additional screening of  
487 metabolites reported in the literature allowed the identification of four compounds derived  
488 from the antibiotics trimethoprim, clindamycin, and ciprofloxacin, illustrating the interest of  
489 including metabolites and transformation products as well in monitoring studies and to derive  
490 ecotoxicological and resistance thresholds for these compounds.

491 **ACKNOWLEDGMENTS**

492 Authors from UJI acknowledge financial support from Project PID2021-127451OB-I00  
493 funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe,the  
494 General Directorate of Water (Conselleria de Agricultura, Desarrollo Rural,  
495 EmergenciaClimática y TransiciónEcológica), ,Generalitat Valenciana (research group of  
496 excellence PROMETEO 2019/040) and University Jaume I (project UJI-B2022-16). L.B. and  
497 E.G.M. acknowledge “la Caixa” Foundation (LCF/BQ/PR21/11840012, project ID  
498 100010434).L.B. also acknowledges grant RYC2020-028936-I funded by MCIN/AEI/  
499 10.13039/501100011033 and by “ESF Investing in your future”. A.R. thanks the Talented  
500 Researcher Support Programme - PlanGenT (CIDEAGENT/2020/043) of the Generalitat  
501 Valenciana. D.F.S was supported by the Margarita Salas postdoctoral contract  
502 MGS/2021/15(UP2021-021) financed by the European Union-NextGenerationEU. Finally,  
503 all authors acknowledge Sociedad de FomentoAgrícolaCastellonense (FACSA) (Castelló,  
504 Spain) for the wastewater sample collection and the Ayuntamiento of Castelló for the  
505 authorization to collect wastewater samples from the WWTP.

506

507 **CRedit authorship contribution statement**

508 **Elisa Gracia-Marín:** Writing – original draft, Methodology, Formal analysis, Data curation,  
509 Visualization; **Andreu Rico:** Writing – original draft; Investigation, Formal analysis, Data  
510 Curation; **David Fabregat-Safont:** Writing – original draft, Investigation, Formal analysis,  
511 Data Curation; **Francisco J. López:** Writing – original draft, Investigation, Formal analysis,  
512 Data Curation; **Félix Hernández:** Resources, Funding acquisition, Writing – review &  
513 editing; **Elena Pitarch:** Project administration, Funding acquisition, Conceptualization,  
514 Supervision, Writing – review & editing; **Lubertus Bijlsma:** Funding acquisition,  
515 Conceptualization, Supervision, Data curation, Writing – review & editing.

516

517 **REFERENCES**

- 518 Aldenberg, T., & Jaworska, J. S. (2000). Uncertainty of the hazardous concentration and fraction  
519 affected for normal species sensitivity distributions. In *Ecotoxicology and Environmental Safety*  
520 (Vol. 46, Issue 1, pp. 1–18). Academic Press. <https://doi.org/10.1006/eesa.1999.1869>
- 521 Aminov, R. I. (2010). A brief history of the antibiotic era: Lessons learned and challenges for the  
522 future. *Frontiers in Microbiology*, 1(DEC). <https://doi.org/10.3389/fmicb.2010.00134>
- 523 Behera, S. K., Kim, H. W., Oh, J. E., & Park, H. S. (2011). Occurrence and removal of antibiotics,  
524 hormones and several other pharmaceuticals in wastewater treatment plants of the largest  
525 industrial city of Korea. *Science of the Total Environment*, 409(20), 4351–4360.  
526 <https://doi.org/10.1016/j.scitotenv.2011.07.015>
- 527 Bengtsson-Palme, J., & Larsson, D. G. J. (2016). Concentrations of antibiotics predicted to select for  
528 resistant bacteria: Proposed limits for environmental regulation. *Environment International*, 86,  
529 140–149. <https://doi.org/10.1016/j.envint.2015.10.015>
- 530 Bijlsma, L., Pitarch, E., Fonseca, E., Ibáñez, M., Botero, A. M., Claros, J., Pastor, L., & Hernández, F.  
531 (2021). Investigation of pharmaceuticals in a conventional wastewater treatment plant:  
532 Removal efficiency, seasonal variation and impact of a nearby hospital. *Journal of*  
533 *Environmental Chemical Engineering*, 9(4). <https://doi.org/10.1016/j.jece.2021.105548>
- 534 Campos-Mañas, M. C., Plaza-Bolaños, P., Sánchez-Pérez, J. A., Malato, S., & Agüera, A. (2017). Fast  
535 determination of pesticides and other contaminants of emerging concern in treated wastewater  
536 using direct injection coupled to highly sensitive ultra-high performance liquid chromatography-  
537 tandem mass spectrometry. *Journal of Chromatography A*, 1507, 84–94.  
538 <https://doi.org/10.1016/j.chroma.2017.05.053>
- 539 Celma, A., Sancho, J. V., Schymanski, E. L., Fabregat-Safont, D., Ibáñez, M., Goshawk, J., Barknowitz,  
540 G., Hernández, F., & Bijlsma, L. (2020). Improving Target and Suspect Screening High-Resolution  
541 Mass Spectrometry Workflows in Environmental Analysis by Ion Mobility Separation.  
542 *Environmental Science and Technology*, 54(23), 15120–15131.  
543 <https://doi.org/10.1021/acs.est.0c05713>
- 544 Desbiolles, F., Malleret, L., Tiliacos, C., Wong-Wah-Chung, P., & Laffont-Schwob, I. (2018). Occurrence  
545 and ecotoxicological assessment of pharmaceuticals: Is there a risk for the Mediterranean  
546 aquatic environment? In *Science of the Total Environment* (Vol. 639, pp. 1334–1348). Elsevier  
547 B.V. <https://doi.org/10.1016/j.scitotenv.2018.04.351>
- 548 Elder, F. C. T., Feil, E. J., Pascoe, B., Sheppard, S. K., Snape, J., Gaze, W. H., & Kasprzyk-Hordern, B.  
549 (2021). Stereoselective Bacterial Metabolism of Antibiotics in Environmental Bacteria – A Novel  
550 Biochemical Workflow. *Frontiers in Microbiology*, 12.  
551 <https://doi.org/10.3389/fmicb.2021.562157>
- 552 EUCAST (2022). *MIC and Zone Diameter Distributions of Wild Type Microorganisms*.  
553 [https://www.eucast.org/mic\\_and\\_zone\\_distributions\\_and\\_ecoffs](https://www.eucast.org/mic_and_zone_distributions_and_ecoffs)
- 554 European Chemicals Agency (ECHA) (2008). *Guidance on information requirements and chemical*  
555 *safety assessment Chapter R.10: Characterisation of dose [concentration]-response for*  
556 *environment Guidance for the implementation of REACH. Helsinki (FI)*.  
557 [http://echa.europa.eu/reach\\_en.asp](http://echa.europa.eu/reach_en.asp)

558 European Commission (2022). Commission Implementing Decision (EU) 2022/1307 of 22 July 2022  
559 establishing a watch list of substances for Union-wide monitoring in the field of water policy  
560 pursuant to Directive 2008/105/EC of the European Parliament of the Council. *Official Journal of*  
561 *the European Union*, L 197, 117–121. [https://eur-lex.europa.eu/legal-](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32022D1307&qid=1679479199865)  
562 [content/EN/TXT/?uri=CELEX%3A32022D1307&qid=1679479199865](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32022D1307&qid=1679479199865)

563 European Commission (2017). *Communication from the Commission to the Council and the European*  
564 *Parliament. A European One Health Action Plan Against Antimicrobial Resistance (AMR).*  
565 <https://eur-lex.europa.eu/legal-content/ES/TXT/?uri=celex%3A52017DC0339>

566 European Commission (2018). Technical Guidance for Deriving Environmental Quality Standards.  
567 Directorate-General for Health and Food Safety. *European Commission Publication Office.*  
568 <https://doi.org/10.2875/018826>

569 Fabregat-Safont, D., Botero-Coy, A. M., Nieto-Juárez, J. I., Torres-Palma, R. A., & Hernández, F.  
570 (2023a). Searching for pharmaceutically active products and metabolites in environmental  
571 waters of Peru by HRMS-based screening: Proposal for future monitoring and environmental  
572 risk assessment. *Chemosphere*, 337, 139375.  
573 <https://doi.org/10.1016/j.chemosphere.2023.139375>

574 Fabregat-Safont, D., Gracia-Marín, E., Ibáñez, M., Pitarch, E., & Hernández, F. (2023b). Analytical key  
575 issues and challenges in the LC-MS/MS determination of antibiotics in wastewater.  
576 *Analytica Chimica Acta*, 1239, 1–10. <https://doi.org/10.1016/j.aca.2022.340739>

577 Fabregat-Safont, D., Ibáñez, M., Bijlsma, L., Hernández, F., Waichman, A. V., de Oliveira, R., & Rico, A.  
578 (2021). Wide-scope screening of pharmaceuticals, illicit drugs and their metabolites in the  
579 Amazon River. *Water Research*, 200. <https://doi.org/10.1016/j.watres.2021.117251>

580 FDA, F. and D. A. (2016, September 28). *FDA, FDA Approved Drug Products: Trimethoprim oral*  
581 *tablets.* [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/018679s044lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018679s044lbl.pdf)

582 FDA, F. and D. A. (2019, September 28). *FDA, FDA Approved Drug Products: Cleocin (clindamycin*  
583 *hydrochloride) oral capsules.*  
584 [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2019/050162s101lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050162s101lbl.pdf)

585 FDA, F. and D. A. (2021). *FDA, FDA Approved Drug Products: CIPRO (ciprofloxacin) oral tablets and*  
586 *suspension.*  
587 [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/019537s093,020780s049lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019537s093,020780s049lbl.pdf)

588 Fonseca, E., Hernández, F., Ibáñez, M., Rico, A., Pitarch, E., & Bijlsma, L. (2020). Occurrence and  
589 ecological risks of pharmaceuticals in a Mediterranean river in Eastern Spain. *Environment*  
590 *International*, 144. <https://doi.org/10.1016/j.envint.2020.106004>

591 Gao, P., Ding, Y., Li, H., & Xagorarakis, I. (2012). Occurrence of pharmaceuticals in a municipal  
592 wastewater treatment plant: Mass balance and removal processes. *Chemosphere*, 88(1), 17–24.  
593 <https://doi.org/10.1016/j.chemosphere.2012.02.017>

594 Goldman, J. L., Leeder, J. S., Van Haandel, L., & Pearce, R. E. (2015). In vitro hepatic oxidative  
595 biotransformation of trimethoprim. *Drug Metabolism and Disposition*, 43(9), 1372–1380.  
596 <https://doi.org/10.1124/dmd.115.065193>



- 597 Golet, E. M., Xifra, I., Siegrist, H., Alder, A. C., & Giger, W. (2003). Environmental exposure assessment  
598 of fluoroquinolone antibacterial agents from sewage to soil. *Environmental Science and*  
599 *Technology*, 37(15), 3243–3249. <https://doi.org/10.1021/es0264448>
- 600 Golovko, O., Örn, S., Söregård, M., Frieberg, K., Nassazzi, W., Lai, F. Y., & Ahrens, L. (2021).  
601 Occurrence and removal of chemicals of emerging concern in wastewater treatment plants and  
602 their impact on receiving water systems. *Science of the Total Environment*, 754.  
603 <https://doi.org/10.1016/j.scitotenv.2020.142122>
- 604 Gullberg, E., Cao, S., Berg, O. G., Ilbäck, C., Sandegren, L., Hughes, D., & Andersson, D. I. (2011).  
605 Selection of resistant bacteria at very low antibiotic concentrations. *PLoS Pathogens*, 7(7).  
606 <https://doi.org/10.1371/journal.ppat.1002158>
- 607 Hanna, N., Tamhankar, A. J., & Lundborg, C. S. (2023). The development of an integrated  
608 environment–human risk approach for the prioritisation of antibiotics for policy decisions.  
609 *Science of the Total Environment*, 880. <https://doi.org/10.1016/j.scitotenv.2023.163301>
- 610 He, K., Soares, A. D., Adejumo, H., McDiarmid, M., Squibb, K., & Blaney, L. (2015). Detection of a wide  
611 variety of human and veterinary fluoroquinolone antibiotics in municipal wastewater and  
612 wastewater-impacted surface water. *Journal of Pharmaceutical and Biomedical Analysis*, 106,  
613 136–143. <https://doi.org/10.1016/j.jpba.2014.11.020>
- 614 Hernández, F., Fabregat-Safont, D., Campos-Mañas, M., & Quintana, J. B. (2023). Efficient Validation  
615 Strategies in Environmental Analytical Chemistry: A Focus on Organic Micropollutants in Water  
616 Samples. *Annual Review of Analytical Chemistry*, 16.
- 617 Ibáñez, M., Bijlsma, L., Pitarch, E., López, F. J., & Hernández, F. (2021). Occurrence of pharmaceutical  
618 metabolites and transformation products in the aquatic environment of the Mediterranean  
619 area. In *Trends in Environmental Analytical Chemistry* (Vol. 29). Elsevier B.V.  
620 <https://doi.org/10.1016/j.teac.2021.e00118>
- 621 Ibáñez, M., Borova, V., Boix, C., Aalizadeh, R., Bade, R., Thomaidis, N. S., & Hernández, F. (2017).  
622 UHPLC-QTOF MS screening of pharmaceuticals and their metabolites in treated wastewater  
623 samples from Athens. *Journal of Hazardous Materials*, 323, 26–35.  
624 <https://doi.org/10.1016/j.jhazmat.2016.03.078>
- 625 Instituto Nacional de Estadística. (2023, April 22). *Castellón/Castelló: Población por municipios y sexo*.  
626 <https://www.ine.es/jaxiT3/Tabla.htm?t=2865&L=0>
- 627 Karthikeyan, K. G., & Meyer, M. T. (2006). Occurrence of antibiotics in wastewater treatment facilities  
628 in Wisconsin, USA. *Science of the Total Environment*, 361(1–3), 196–207.  
629 <https://doi.org/10.1016/j.scitotenv.2005.06.030>
- 630 Kelly, K. R., & Brooks, B. W. (2018). Global Aquatic Hazard Assessment of Ciprofloxacin: Exceedances  
631 of Antibiotic Resistance Development and Ecotoxicological Thresholds. In *Progress in Molecular*  
632 *Biology and Translational Science* (Vol. 159, pp. 59–77). Elsevier B.V.  
633 <https://doi.org/10.1016/bs.pmbts.2018.07.004>
- 634 Kovalakova, P., Cizmas, L., McDonald, T. J., Marsalek, B., Feng, M., & Sharma, V. K. (2020). Occurrence  
635 and toxicity of antibiotics in the aquatic environment: A review. In *Chemosphere* (Vol. 251).  
636 Elsevier Ltd. <https://doi.org/10.1016/j.chemosphere.2020.126351>

- 637 Kumar, M., Jaiswal, S., Sodhi, K. K., Shree, P., Singh, D. K., Agrawal, P. K., & Shukla, P. (2019).  
638 Antibiotics bioremediation: Perspectives on its ecotoxicity and resistance. In *Environment*  
639 *International* (Vol. 124, pp. 448–461). Elsevier Ltd. <https://doi.org/10.1016/j.envint.2018.12.065>
- 640 Lacey, C., McMahon, G., Bones, J., Barron, L., Morrissey, A., & Tobin, J. M. (2008). An LC-MS method  
641 for the determination of pharmaceutical compounds in wastewater treatment plant influent  
642 and effluent samples. *Talanta*, 75(4), 1089–1097. <https://doi.org/10.1016/j.talanta.2008.01.011>
- 643 Le Page, G., Gunnarsson, L., Snape, J., & Tyler, C. R. (2017). Integrating human and environmental  
644 health in antibiotic risk assessment: A critical analysis of protection goals, species sensitivity and  
645 antimicrobial resistance. In *Environment International* (Vol. 109, pp. 155–169). Elsevier Ltd.  
646 <https://doi.org/10.1016/j.envint.2017.09.013>
- 647 LeBel, M. (1988). Ciprofloxacin: Chemistry, Mechanism of Action, Resistance, Antimicrobial Spectrum,  
648 Pharmacokinetics, Clinical Trials, and Adverse Reactions. *Pharmacotherapy: The Journal of*  
649 *Human Pharmacology and Drug Therapy*, 8(1), 3–30. [https://doi.org/10.1002/j.1875-](https://doi.org/10.1002/j.1875-9114.1988.tb04058.x)  
650 [9114.1988.tb04058.x](https://doi.org/10.1002/j.1875-9114.1988.tb04058.x)
- 651 Lien, L. T. Q., Hoa, N. Q., Chuc, N. T. K., Thoa, N. T. M., Phuc, H. D., Diwan, V., Dat, N. T., Tamhankar,  
652 A. J., & Lundborg, C. S. (2016a). Antibiotics in wastewater of a rural and an urban hospital  
653 before and after wastewater treatment, and the relationship with antibiotic use-a one year  
654 study from Vietnam. *International Journal of Environmental Research and Public Health*, 13(6).  
655 <https://doi.org/10.3390/ijerph13060588>
- 656 Lien, L. T. Q., Hoa, N. Q., Chuc, N. T. K., Thoa, N. T. M., Phuc, H. D., Diwan, V., Dat, N. T., Tamhankar,  
657 A. J., & Lundborg, C. S. (2016b). Antibiotics in wastewater of a rural and an urban hospital  
658 before and after wastewater treatment, and the relationship with antibiotic use-a one year  
659 study from Vietnam. *International Journal of Environmental Research and Public Health*, 13(6).  
660 <https://doi.org/10.3390/ijerph13060588>
- 661 Liu, A., Fong, A., Becket, E., Yuan, J., Tamae, C., Medrano, L., Maiz, M., Wahba, C., Lee, C., Lee, K.,  
662 Tran, K. P., Yang, H., Hoffman, R. M., Salih, A., & Miller, J. H. (2011). Selective advantage of  
663 resistant strains at trace levels of antibiotics: A simple and ultrasensitive color test for detection  
664 of antibiotics and genotoxic agents. *Antimicrobial Agents and Chemotherapy*, 55(3), 1204–1210.  
665 <https://doi.org/10.1128/AAC.01182-10>
- 666 Löffler, P., Escher, B. I., Baduel, C., Virta, M. P., & Lai, F. Y. (2023). Antimicrobial Transformation  
667 Products in the Aquatic Environment: Global Occurrence, Ecotoxicological Risks, and Potential  
668 of Antibiotic Resistance. *Environmental Science & Technology*.  
669 <https://doi.org/10.1021/acs.est.2c09854>
- 670 Lopez, F. J., Pitarch, E., Botero-Coy, A. M., Fabregat-Safont, D., Ibáñez, M., Marin, J. M., Peruga, A.,  
671 Ontañón, N., Martínez-Morcillo, S., Olalla, A., Valcárcel, Y., Varó, I., & Hernández, F. (2022).  
672 Removal efficiency for emerging contaminants in a WWTP from Madrid (Spain) after secondary  
673 and tertiary treatment and environmental impact on the Manzanares River. *Science of the Total*  
674 *Environment*, 812. <https://doi.org/10.1016/j.scitotenv.2021.152567>
- 675 Luo, Y., Guo, W., Ngo, H. H., Nghiem, L. D., Hai, F. I., Zhang, J., Liang, S., & Wang, X. C. (2014). A  
676 review on the occurrence of micropollutants in the aquatic environment and their fate and  
677 removal during wastewater treatment. In *Science of the Total Environment* (Vols. 473–474, pp.  
678 619–641). Elsevier B.V. <https://doi.org/10.1016/j.scitotenv.2013.12.065>

- 679 Martínez-Piernas, A. B., Plaza-Bolaños, P., & Agüera, A. (2021). Assessment of the presence of  
680 transformation products of pharmaceuticals in agricultural environments irrigated with  
681 reclaimed water by wide-scope LC-QTOF-MS suspect screening. *Journal of Hazardous Materials*,  
682 412. <https://doi.org/10.1016/j.jhazmat.2021.125080>
- 683 McCorquodale-Bauer, K., Grosshans, R., Zvomuya, F., & Cicek, N. (2023). Critical review of  
684 phytoremediation for the removal of antibiotics and antibiotic resistance genes in wastewater.  
685 *Science of The Total Environment*, 161876. <https://doi.org/10.1016/j.scitotenv.2023.161876>
- 686 Pereira, A., Silva, L., Laranjeiro, C., Lino, C., & Pena, A. (2020). Selected pharmaceuticals in different  
687 aquatic compartments: Part I—Source, fate and occurrence. In *Molecules* (Vol. 25, Issue 5).  
688 MDPI AG. <https://doi.org/10.3390/molecules25051026>
- 689 Plan Nacional Resistencia Antibioticos (PRAN). (2023). *Mapas de consumo de antibioticos*.  
690 [https://resistenciaantibioticos.es/es/lineas-de-accion/vigilancia/mapas-de-consumo/consumo-](https://resistenciaantibioticos.es/es/lineas-de-accion/vigilancia/mapas-de-consumo/consumo-antibioticos-humana)  
691 [antibioticos-humana](https://resistenciaantibioticos.es/es/lineas-de-accion/vigilancia/mapas-de-consumo/consumo-antibioticos-humana)
- 692 Pruden, A., Joakim Larsson, D. G., Amézquita, A., Collignon, P., Brandt, K. K., Graham, D. W.,  
693 Lazorchak, J. M., Suzuki, S., Silley, P., Snape, J. R., Topp, E., Zhang, T., & Zhu, Y. G. (2013).  
694 Management options for reducing the release of antibiotics and antibiotic resistance genes to  
695 the environment. In *Environmental Health Perspectives* (Vol. 121, Issue 8, pp. 878–885).  
696 <https://doi.org/10.1289/ehp.1206446>
- 697 Rico, A., Jacobs, R., Van den Brink, P. J., & Tello, A. (2017). A probabilistic approach to assess  
698 antibiotic resistance development risks in environmental compartments and its application to  
699 an intensive aquaculture production scenario. *Environmental Pollution*, 231, 918–928.  
700 <https://doi.org/10.1016/j.envpol.2017.08.079>
- 701 Rodriguez-Mozaz, S., Vaz-Moreira, I., Varela Della Giustina, S., Llorca, M., Barceló, D., Schubert, S.,  
702 Berendonk, T. U., Michael-Kordatou, I., Fatta-Kassinos, D., Martinez, J. L., Elpers, C., Henriques,  
703 I., Jaeger, T., Schwartz, T., Paulshus, E., O’Sullivan, K., Pärnänen, K. M. M., Virta, M., Do, T. T., ...  
704 Manaia, C. M. (2020). Antibiotic residues in final effluents of European wastewater treatment  
705 plants and their impact on the aquatic environment. *Environment International*, 140.  
706 <https://doi.org/10.1016/j.envint.2020.105733>
- 707 Rogers, H. R. (1996). Sources, behaviour and fate of organic contaminants during sewage treatment  
708 and in sewage sludges. *The Science of the Total Environment*, 185, 3–26.
- 709 Roose-Amsaleg, C., & Laverman, A. M. (2016). Do antibiotics have environmental side-effects? Impact  
710 of synthetic antibiotics on biogeochemical processes. *Environmental Science and Pollution*  
711 *Research*, 23(5), 4000–4012. <https://doi.org/10.1007/s11356-015-4943-3>
- 712 Sabri, N. A., van Holst, S., Schmitt, H., van der Zaan, B. M., Gerritsen, H. W., Rijnaarts, H. H. M.,  
713 & Langenhoff, A. A. M. (2020a). Fate of antibiotics and antibiotic resistance genes during  
714 conventional and additional treatment technologies in wastewater treatment plants. *Science of*  
715 *the Total Environment*, 741. <https://doi.org/10.1016/j.scitotenv.2020.140199>
- 716 Sabri, N. A., van Holst, S., Schmitt, H., van der Zaan, B. M., Gerritsen, H. W., Rijnaarts, H. H. M.,  
717 & Langenhoff, A. A. M. (2020b). Fate of antibiotics and antibiotic resistance genes during  
718 conventional and additional treatment technologies in wastewater treatment plants. *Science of*  
719 *the Total Environment*, 741. <https://doi.org/10.1016/j.scitotenv.2020.140199>

- 720 SANTE (2021). Analytical quality control and method validation procedures for pesticide residues  
721 analysis in food and feed SANTE 11312/2021.
- 722 Seifrtová, M., Aufartová, J., Vytlačilová, J., Pena, A., Solich, P., & Nováková, L. (2010). Determination  
723 of fluoroquinolone antibiotics in wastewater using ultra high-performance liquid  
724 chromatography with mass spectrometry and fluorescence detection.  
725 *Journal of Separation Science*, 33(14), 2094–2108. <https://doi.org/10.1002/jssc.201000215>
- 726 Solaun, O., Rodríguez, J. G., Borja, Á., López-García, E., Zonja, B., Postigo, C., Barceló, D., de Alda, M.  
727 L., & Larreta, J. (2022). Antibiotics in the Basque coast (N Spain): Occurrence in waste and  
728 receiving waters, and risk assessment (2017–2020). *Science of the Total Environment*, 847.  
729 <https://doi.org/10.1016/j.scitotenv.2022.157563>
- 730 Subedi, B., Lee, S., Moon, H. B., & Kannan, K. (2014). Emission of artificial sweeteners, select  
731 pharmaceuticals, and personal care products through sewage sludge from wastewater  
732 treatment plants in Korea. *Environment International*, 68, 33–40.  
733 <https://doi.org/10.1016/j.envint.2014.03.006>
- 734 Tell, J., Caldwell, D. J., Häner, A., Hellstern, J., Hoeger, B., Journal, R., Mastrocco, F., Ryan, J. J., Snape,  
735 J., Straub, J. O., & Vestel, J. (2019). Science-based Targets for Antibiotics in Receiving Waters  
736 from Pharmaceutical Manufacturing Operations. *Integrated Environmental Assessment and  
737 Management*, 15(3), 312–319. <https://doi.org/10.1002/ieam.4141>
- 738 Van Hoi, B., Vu, C. T., Phung-Thi, L. A., Thi Nguyen, T., Nguyen, P. T., Mai, H., Le, P. T., Nguyen, T. H.,  
739 Thanh Duong, D., Nguyen Thi, H., Le-Van, D., & Chu, D. B. (2021). Determination of  
740 Pharmaceutical Residues by UPLC-MS/MS Method: Validation and Application on Surface Water  
741 and Hospital Wastewater. *Journal of Analytical Methods in Chemistry*, 2021.  
742 <https://doi.org/10.1155/2021/6628285>
- 743 Van Vlaardingen, P. L. A., Traas, T. P., Wintersen, A. M., & Aldenberg, T. (2004). *E T X 2.0 A Program  
744 to Calculate Hazardous Concentrations and Fraction Affected, Based on Normally Distributed  
745 Toxicity Data. Report no. 601501028/2004.*
- 746 Verlicchi, P., Al Aukidy, M., & Zambello, E. (2012). Occurrence of pharmaceutical compounds in urban  
747 wastewater: Removal, mass load and environmental risk after a secondary treatment-A review.  
748 In *Science of the Total Environment* (Vol. 429, pp. 123–155).  
749 <https://doi.org/10.1016/j.scitotenv.2012.04.028>
- 750 Vieno, N., Tuhkanen, T., & Kronberg, L. (2007). Elimination of pharmaceuticals in sewage treatment  
751 plants in Finland. *Water Research*, 41(5), 1001–1012.  
752 <https://doi.org/10.1016/j.watres.2006.12.017>
- 753 Watkinson, A. J., Murby, E. J., & Costanzo, S. D. (2007). Removal of antibiotics in conventional and  
754 advanced wastewater treatment: Implications for environmental discharge and wastewater  
755 recycling. *Water Research*, 41(18), 4164–4176. <https://doi.org/10.1016/j.watres.2007.04.005>
- 756 WHO, W. H. O. (2019). *Critically Important Antimicrobials for Human Medicine 6th Revision 2018  
757 Ranking of medically important antimicrobials for risk management of antimicrobial resistance  
758 due to non-human use.* [https://apps.who.int/iris/bitstream/handle/  
759 10665/312266/9789241515528-eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/312266/9789241515528-eng.pdf)
- 760 WHO, W. H. O. (2023, December 10). *Global Antimicrobial Resistance and Use Surveillance System  
761 (GLASS).* <https://www.who.int/initiatives/glass>

- 762 Wielens Becker, R., Ibáñez, M., Cuervo Lumbaque, E., Wilde, M. L., Flores da Rosa, T., Hernández, F.,  
763 & Sirtori, C. (2020). Investigation of pharmaceuticals and their metabolites in Brazilian hospital  
764 wastewater by LC-QTOF MS screening combined with a preliminary exposure and in silico risk  
765 assessment. *Science of the Total Environment*, 699.  
766 <https://doi.org/10.1016/j.scitotenv.2019.134218>
- 767 Wilkinson, J. L., Boxall, A. B. A., Kolpin, D. W., & Kenneth, M. Y. L. (2022). *Pharmaceutical pollution of*  
768 *the world's rivers*. <https://doi.org/10.1073/pnas.2113947119/-/DCSupplemental>
- 769 Yan, Q., Gao, X., Chen, Y. P., Peng, X. Y., Zhang, Y. X., Gan, X. M., Zi, C. F., & Guo, J. S. (2014).  
770 Occurrence, fate and ecotoxicological assessment of pharmaceutically active compounds in  
771 wastewater and sludge from wastewater treatment plants in Chongqing, the Three Gorges  
772 Reservoir Area. *Science of the Total Environment*, 470–471, 618–630.  
773 <https://doi.org/10.1016/j.scitotenv.2013.09.032>
- 774 Zuccato, E., Castiglioni, S., Bagnati, R., Melis, M., & Fanelli, R. (2010). Source, occurrence and fate of  
775 antibiotics in the Italian aquatic environment. *Journal of Hazardous Materials*, 179(1–3), 1042–  
776 1048. <https://doi.org/10.1016/j.jhazmat.2010.03.110>
- 777 Zuccato, E., Castiglioni, S., & Fanelli, R. (2005). Identification of the pharmaceuticals for human use  
778 contaminating the Italian aquatic environment. *Journal of Hazardous Materials*, 122(3), 205–  
779 209. <https://doi.org/10.1016/j.jhazmat.2005.03.001>
- 780